Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer

BACKGROUND: The discovery of checkpoint inhibitors towards cytotoxic T-lymphocyte protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) has been revolutionary for the treatment of cancers. These therapies have only offered an average of 20%–30% response rates across the tumor spectrum and th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Tianhang, Wang, Chao, Xu, Yifeng, Huang, Weifeng, Yuan, Zhijun, Wang, Tao, Dai, Shuang, Peng, Shaogang, Pang, Tuling, Jiang, Wenchao, Huang, Yuhua, Zou, Yuefeng, Xu, Yingda, Sun, Joanne, Gong, Xinjiang, Zhang, Jinping, Tsun, Andy, Li, Bin, Miao, Xiaoniu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237747/
https://www.ncbi.nlm.nih.gov/pubmed/34172514
http://dx.doi.org/10.1136/jitc-2020-002131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237747/
https://www.ncbi.nlm.nih.gov/pubmed/34172514
http://dx.doi.org/10.1136/jitc-2020-002131

Ejemplares similares